SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: j_fir2 who wrote (1111)3/21/2000 10:39:00 AM
From: j_fir2  Read Replies (1) of 1386
 
THALIDOMIDE BENEFITS PATIENTS WITH MULTIPLE MYELOMA
Patients with refractory or relapsed multiple myeloma benefit from
thalidomide treatment, Israeli researchers report in the February issue of
the British Journal of Haematology.
pharmacotherapy.medscape.com
<a href="http://pharmacotherapy.medscape.com/18893.rhtml">Read it Here</a>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News